SAUDI ARABIA

SFDA withdraws “Jusprin 81 mg” from market due to quality flaws

January 22, 2019

RIYADH – The Saudi Food and Drug Authority (SFDA) has withdrawn the medicine “Jusprin 81 mg” from the market due to quality flaws, Saudi Press Agency (SPA) said.

The SFDA has also written to health authorities to stop using the medicine.

This measure has come after the SFDA received information from Julphar, the manufacturing company, that all batches and forms of Jusprin 81 mg have quality flaws. As a result, the Authority has forced Julphar to withdraw all batches and forms of the medicine from all facilities dispensing the drug. It called on those using the medicine to see their doctors.

For those who need more information, the SFDA has called on the public to call the Unified Call Center number 19999 at the SFDA. – SPA


January 22, 2019
13573 views
HIGHLIGHTS
SAUDI ARABIA
3 hours ago

FDI inflows to Saudi Arabia jump 16%, reaching over SR13 billion in 4Q of 2023

SAUDI ARABIA
3 hours ago

Saudi pavilion to showcase Manal AlDowayan's 'Shifting Sands: A Battle Song' at Venice Biennale

SAUDI ARABIA
3 hours ago

Red Sea International Airport to welcome first foreign flight in April